These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 39076437)
1. Recent Advances in the Mechanisms of Cell Death and Dysfunction in Doxorubicin Cardiotoxicity. Wang TH; Ma Y; Gao S; Zhang WW; Han D; Cao F Rev Cardiovasc Med; 2023 Nov; 24(11):336. PubMed ID: 39076437 [TBL] [Abstract][Full Text] [Related]
2. Regulated cell death pathways in doxorubicin-induced cardiotoxicity. Christidi E; Brunham LR Cell Death Dis; 2021 Apr; 12(4):339. PubMed ID: 33795647 [TBL] [Abstract][Full Text] [Related]
4. Vagus nerve stimulation exerts cardioprotection against doxorubicin-induced cardiotoxicity through inhibition of programmed cell death pathways. Prathumsap N; Ongnok B; Khuanjing T; Arinno A; Maneechote C; Apaijai N; Chunchai T; Arunsak B; Kerdphoo S; Janjek S; Chattipakorn SC; Chattipakorn N Cell Mol Life Sci; 2022 Dec; 80(1):21. PubMed ID: 36583785 [TBL] [Abstract][Full Text] [Related]
5. Pretreatment of 3-MA prevents doxorubicin-induced cardiotoxicity through inhibition of autophagy initiation. Sun X; Meng H; Xiao J; Liu F; Du J; Zeng H Toxicology; 2023 May; 490():153512. PubMed ID: 37062353 [TBL] [Abstract][Full Text] [Related]
6. The Interplay Between Autophagy and Senescence in Anthracycline Cardiotoxicity. Russo M; Bono E; Ghigo A Curr Heart Fail Rep; 2021 Aug; 18(4):180-190. PubMed ID: 34081265 [TBL] [Abstract][Full Text] [Related]
7. Cell death regulation in myocardial toxicity induced by antineoplastic drugs. Yu X; Yang Y; Chen T; Wang Y; Guo T; Liu Y; Li H; Yang L Front Cell Dev Biol; 2023; 11():1075917. PubMed ID: 36824370 [TBL] [Abstract][Full Text] [Related]
8. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management. Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; CalabrĂ² R Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628 [TBL] [Abstract][Full Text] [Related]
9. Cardioprotection in cancer therapy: novel insights with anthracyclines. Raber I; Asnani A Cardiovasc Res; 2019 Apr; 115(5):915-921. PubMed ID: 30726931 [TBL] [Abstract][Full Text] [Related]
10. Understanding Anthracycline Cardiotoxicity From Mitochondrial Aspect. Huang J; Wu R; Chen L; Yang Z; Yan D; Li M Front Pharmacol; 2022; 13():811406. PubMed ID: 35211017 [TBL] [Abstract][Full Text] [Related]
11. Gasdermin D mediates doxorubicin-induced cardiomyocyte pyroptosis and cardiotoxicity via directly binding to doxorubicin and changes in mitochondrial damage. Ye B; Shi X; Xu J; Dai S; Xu J; Fan X; Han B; Han J Transl Res; 2022 Oct; 248():36-50. PubMed ID: 35545198 [TBL] [Abstract][Full Text] [Related]
12. Doxorubicin induces cardiomyocyte pyroptosis via the TINCR-mediated posttranscriptional stabilization of NLR family pyrin domain containing 3. Meng L; Lin H; Zhang J; Lin N; Sun Z; Gao F; Luo H; Ni T; Luo W; Chi J; Guo H J Mol Cell Cardiol; 2019 Nov; 136():15-26. PubMed ID: 31445005 [TBL] [Abstract][Full Text] [Related]
13. Human Pluripotent Stem Cell-Derived Cardiomyocytes for Assessment of Anticancer Drug-Induced Cardiotoxicity. Schwach V; Slaats RH; Passier R Front Cardiovasc Med; 2020; 7():50. PubMed ID: 32322588 [TBL] [Abstract][Full Text] [Related]
14. Anthracycline-induced cardiotoxicity: From pathobiology to identification of molecular targets for nuclear imaging. Jong J; Pinney JR; Packard RRS Front Cardiovasc Med; 2022; 9():919719. PubMed ID: 35990941 [TBL] [Abstract][Full Text] [Related]
15. HDL protects against doxorubicin-induced cardiotoxicity in a scavenger receptor class B type 1-, PI3K-, and Akt-dependent manner. Durham KK; Chathely KM; Mak KC; Momen A; Thomas CT; Zhao YY; MacDonald ME; Curtis JM; Husain M; Trigatti BL Am J Physiol Heart Circ Physiol; 2018 Jan; 314(1):H31-H44. PubMed ID: 28986362 [TBL] [Abstract][Full Text] [Related]
16. Loss of TRIM21 alleviates cardiotoxicity by suppressing ferroptosis induced by the chemotherapeutic agent doxorubicin. Hou K; Shen J; Yan J; Zhai C; Zhang J; Pan JA; Zhang Y; Jiang Y; Wang Y; Lin RZ; Cong H; Gao S; Zong WX EBioMedicine; 2021 Jul; 69():103456. PubMed ID: 34233258 [TBL] [Abstract][Full Text] [Related]
17. Amentoflavone mitigates doxorubicin-induced cardiotoxicity by suppressing cardiomyocyte pyroptosis and inflammation through inhibition of the STING/NLRP3 signalling pathway. Fang G; Li X; Yang F; Huang T; Qiu C; Peng K; Wang Z; Yang Y; Lan C Phytomedicine; 2023 Aug; 117():154922. PubMed ID: 37321078 [TBL] [Abstract][Full Text] [Related]
18. Anthracycline-induced cardiotoxicity and cell senescence: new therapeutic option? Seara FAC; Kasai-Brunswick TH; Nascimento JHM; Campos-de-Carvalho AC Cell Mol Life Sci; 2022 Oct; 79(11):568. PubMed ID: 36287277 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of cyclin-dependent kinase 2 protects against doxorubicin-induced cardiomyocyte apoptosis and cardiomyopathy. Xia P; Liu Y; Chen J; Coates S; Liu DX; Cheng Z J Biol Chem; 2018 Dec; 293(51):19672-19685. PubMed ID: 30361442 [TBL] [Abstract][Full Text] [Related]
20. Dexrazoxane ameliorates doxorubicin-induced cardiotoxicity by inhibiting both apoptosis and necroptosis in cardiomyocytes. Yu X; Ruan Y; Huang X; Dou L; Lan M; Cui J; Chen B; Gong H; Wang Q; Yan M; Sun S; Qiu Q; Zhang X; Man Y; Tang W; Li J; Shen T Biochem Biophys Res Commun; 2020 Feb; 523(1):140-146. PubMed ID: 31837803 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]